Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gauri R Varadhachary

Showing results (51-60 of 113) with videos related to

Pageof 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2011
Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primaryGauri R Varadhachary, Yael Spector, James L Abbruzzese, et al.
Journal of Cachexia, Sarcopenia and Muscle|April 18, 2014
Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?David R Fogelman, Holly Holmes, Khalil Mohammed, et al.
Investigational New Drugs|January 29, 2010
A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancerBassel Fuad El-Rayes, Philip A Philip, Fazlul H Sarkar, et al.
Cancer Medicine|June 11, 2020
Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinomaJane E Rogers, Jonathan D Mizrahi, Lianchun Xiao, et al.
Journal of the American College of Surgeons|February 28, 2007
Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy?Thomas A Aloia, Thomas E Aloia, Jeffrey E Lee, et al.
Annals of Diagnostic Pathology|November 5, 2011
Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosisQing Zhao, Asif Rashid, Yun Gong, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|January 15, 2020
Modified FOLFIRINOX in pancreatic cancer patients Age 75 or olderJonathan D Mizrahi, Jane E Rogers, Kenneth R Hess, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|October 17, 2013
Morbidity and mortality after pancreaticoduodenectomy in patients with borderline resectable type C clinical classificationChing-Wei D Tzeng, Matthew H G Katz, Jason B Fleming, et al.
Histopathology|May 7, 2015
The number and ratio of positive lymph nodes affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomyLaurice K Fischer, Matthew H Katz, Sun M Lee, et al.
Annals of Surgical Oncology|February 15, 2013
Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysisChing-Wei D Tzeng, Daniel E Abbott, Scott B Cantor, et al.
Pageof 12

Showing results (51-60 of 113) with videos related to

Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2011
Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primaryGauri R Varadhachary, Yael Spector, James L Abbruzzese, et al.
Journal of Cachexia, Sarcopenia and Muscle|April 18, 2014
Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?David R Fogelman, Holly Holmes, Khalil Mohammed, et al.
Investigational New Drugs|January 29, 2010
A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancerBassel Fuad El-Rayes, Philip A Philip, Fazlul H Sarkar, et al.
Cancer Medicine|June 11, 2020
Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinomaJane E Rogers, Jonathan D Mizrahi, Lianchun Xiao, et al.
Journal of the American College of Surgeons|February 28, 2007
Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy?Thomas A Aloia, Thomas E Aloia, Jeffrey E Lee, et al.
Annals of Diagnostic Pathology|November 5, 2011
Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosisQing Zhao, Asif Rashid, Yun Gong, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|January 15, 2020
Modified FOLFIRINOX in pancreatic cancer patients Age 75 or olderJonathan D Mizrahi, Jane E Rogers, Kenneth R Hess, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|October 17, 2013
Morbidity and mortality after pancreaticoduodenectomy in patients with borderline resectable type C clinical classificationChing-Wei D Tzeng, Matthew H G Katz, Jason B Fleming, et al.
Histopathology|May 7, 2015
The number and ratio of positive lymph nodes affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomyLaurice K Fischer, Matthew H Katz, Sun M Lee, et al.
Annals of Surgical Oncology|February 15, 2013
Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysisChing-Wei D Tzeng, Daniel E Abbott, Scott B Cantor, et al.
Pageof 12